temozolomide has been researched along with Rectal Neoplasms in 6 studies
Rectal Neoplasms: Tumors or cancer of the RECTUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Temozolomide was administered orally once per day at a dosage of 200 mg/m2/d for five consecutive days about every 4 weeks." | 5.56 | Transcatheter arterial infusion of anti-programmed cell death 1 antibody pembrolizumab combined with temozolomide or nab-paclitaxel in patient with primary anorectal malignant melanoma: Four case reports. ( Cao, F; Chen, S; Fan, W; Li, D; Ma, W; Qi, H; Shen, L; Song, Z; Wen, X; Wu, Y; Xie, L; Zhang, X, 2020) |
| "33 patients with brain metastases were included in the study and treated with TMZ 60 mg/m2/day (days 1-16) concomitantly with WBI (36 Gy/12 fractions given in 16 days)." | 2.73 | Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors. ( Balafouta, MJ; Kolokouris, D; Kouloulias, VE; Kouvaris, JR; Miliadou, A; Papacharalampous, XN; Vlahos, LJ, 2007) |
| "Temozolomide was administered orally once per day at a dosage of 200 mg/m2/d for five consecutive days about every 4 weeks." | 1.56 | Transcatheter arterial infusion of anti-programmed cell death 1 antibody pembrolizumab combined with temozolomide or nab-paclitaxel in patient with primary anorectal malignant melanoma: Four case reports. ( Cao, F; Chen, S; Fan, W; Li, D; Ma, W; Qi, H; Shen, L; Song, Z; Wen, X; Wu, Y; Xie, L; Zhang, X, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morano, F | 1 |
| Raimondi, A | 1 |
| Pagani, F | 1 |
| Lonardi, S | 1 |
| Salvatore, L | 1 |
| Cremolini, C | 1 |
| Murgioni, S | 1 |
| Randon, G | 1 |
| Palermo, F | 1 |
| Antonuzzo, L | 1 |
| Pella, N | 1 |
| Racca, P | 1 |
| Prisciandaro, M | 1 |
| Niger, M | 1 |
| Corti, F | 1 |
| Bergamo, F | 1 |
| Zaniboni, A | 1 |
| Ratti, M | 1 |
| Palazzo, M | 1 |
| Cagnazzo, C | 1 |
| Calegari, MA | 1 |
| Marmorino, F | 1 |
| Capone, I | 1 |
| Conca, E | 1 |
| Busico, A | 1 |
| Brich, S | 1 |
| Tamborini, E | 1 |
| Perrone, F | 1 |
| Di Maio, M | 1 |
| Milione, M | 1 |
| Di Bartolomeo, M | 1 |
| de Braud, F | 1 |
| Pietrantonio, F | 1 |
| Oh, CR | 1 |
| Kim, JE | 2 |
| Lee, JS | 1 |
| Kim, SY | 2 |
| Kim, TW | 2 |
| Choi, J | 1 |
| Kim, J | 2 |
| Park, IJ | 2 |
| Lim, SB | 2 |
| Park, JH | 2 |
| Kim, JH | 2 |
| Choi, MK | 1 |
| Cha, Y | 1 |
| Baek, JY | 1 |
| Beom, SH | 1 |
| Hong, YS | 2 |
| Chen, S | 1 |
| Zhang, X | 1 |
| Shen, L | 1 |
| Qi, H | 1 |
| Ma, W | 1 |
| Cao, F | 1 |
| Xie, L | 1 |
| Song, Z | 1 |
| Wu, Y | 1 |
| Li, D | 1 |
| Wen, X | 1 |
| Fan, W | 1 |
| Jeong, JH | 1 |
| Park, Y | 1 |
| Kim, KP | 1 |
| Yu, CS | 1 |
| Kim, JC | 1 |
| Weller, M | 1 |
| Kouvaris, JR | 1 |
| Miliadou, A | 1 |
| Kouloulias, VE | 1 |
| Kolokouris, D | 1 |
| Balafouta, MJ | 1 |
| Papacharalampous, XN | 1 |
| Vlahos, LJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study[NCT03832621] | Phase 2 | 135 participants (Actual) | Interventional | 2019-03-25 | Completed | ||
| Preoperative Chemoradiation With Capecitabine Plus Temozolomide in Patients With Locally Advanced Resectable Rectal Cancer: Phase I Study[NCT01781403] | Phase 1 | 22 participants (Actual) | Interventional | 2013-05-10 | Completed | ||
| Multicenter Phase II Study of Preoperative Chemoradiotherapy With CApecitabine Plus Temozolomide in Patients With MGMT Silenced and Microsatellite Stable Locally Advanced RecTal Cancer: the CATARTIC Trial[NCT05136326] | Phase 2 | 21 participants (Anticipated) | Interventional | 2021-12-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The MTD is defined as the maximum dose level in the doses of temozolomide tested with capecitabine and radiation in which the incidence proportion of DLT exceeds 30%. (NCT01781403)
Timeframe: 5-6 weeks during study treatment
| Intervention | mg/m^2 (Number) |
|---|---|
| Dose Level 1 | 0 |
| Dose Level 2 | 0 |
| Dose Level 3/Recommended Dose | 0 |
"Pathologic responses and stages were classified according to Dworak's classification and the 7th edition of the American Joint Committee on Cancer staging system, respectively.~The pathologic complete response (pCR) was defined as the total regression of the primary tumor regardless of regional lymph nodal status (ypT0), with residual fibrotic mass or acellular mucin pools only, thus without detectable tumor cells." (NCT01781403)
Timeframe: at the time of surgery (6-8 weeks after study treatment)
| Intervention | participants (Number) |
|---|---|
| Unmethylated MGMT | 1 |
| Hypermethylated MGMT | 6 |
RD will be defined as one level below the MTD. (NCT01781403)
Timeframe: 5-6 weeks after CRT
| Intervention | mg/m^2 (Number) |
|---|---|
| Dose Level 1 | 0 |
| Dose Level 2 | 0 |
| Dose Level 3/Recommended Dose | 75 |
"Toxicity will be monitored and recorded every week during study treatment (5 or 6 weeks) as following according to the NCI-CTCAE version 4.0~An interval history and physical examination with particular attention to drug-induced side effects along with documentation of the patient's weight and performance status will be performed on each visit.~CBC with differential count, blood chemistry including calcium, phosphorus, glucose, BUN, creatinine, total protein, albumin, AST, ALT, alkaline phosphatase, total bilirubin, and electrolyte will be performed before next planned treatment.~All relevant information regarding drug dosage, laboratory examinations, and treatment-related toxicities must be recorded before each treatment is given.~Summaries of the frequency and severity of adverse effects are based on the worst episodes recorded." (NCT01781403)
Timeframe: 5-6 weeks during study treatment
| Intervention | events (Number) | |||
|---|---|---|---|---|
| Any grade 1 adverse event | Any grade 2 adverse event | Any grade 3 adverse event | Any grade 4 adverse event | |
| Dose Level 1 | 6 | 2 | 1 | 0 |
| Dose Level 2 | 8 | 2 | 0 | 0 |
| Dose Level 3/Recommended Dose | 60 | 17 | 3 | 0 |
4 trials available for temozolomide and Rectal Neoplasms
| Article | Year |
|---|---|
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Humans; Ipi | 2022 |
Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer: A Prospective, Randomised Phase II Study Stratified by O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Capecitabine; Chemoradiotherapy; Dacarbazine; DN | 2023 |
Phase 1 Study of Preoperative Chemoradiation Therapy With Temozolomide and Capecitabine in Patients With Locally Advanced Rectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Dacarb | 2016 |
Phase 1 Study of Preoperative Chemoradiation Therapy With Temozolomide and Capecitabine in Patients With Locally Advanced Rectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Dacarb | 2016 |
Phase 1 Study of Preoperative Chemoradiation Therapy With Temozolomide and Capecitabine in Patients With Locally Advanced Rectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Dacarb | 2016 |
Phase 1 Study of Preoperative Chemoradiation Therapy With Temozolomide and Capecitabine in Patients With Locally Advanced Rectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Dacarb | 2016 |
Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carci | 2007 |
2 other studies available for temozolomide and Rectal Neoplasms
| Article | Year |
|---|---|
Transcatheter arterial infusion of anti-programmed cell death 1 antibody pembrolizumab combined with temozolomide or nab-paclitaxel in patient with primary anorectal malignant melanoma: Four case reports.
Topics: Adult; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; | 2020 |
Radiochemotherapy for brain metastasis: how to define a role for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | 2007 |